Zydus Lifesciences Expands Rare Disease Portfolio with US Rights Option for Alvelestat

Zydus Lifesciences is strengthening its presence in the rare-disease segment as its wholly owned subsidiary, Sentynl Therapeutics, has entered into an option and licence agreement with Mereo BioPharma for alvelestat, an experimental oral treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD). Under the agreement, Sentynl has the exclusive option to obtain US commercial rights for alvelestat, while Mereo will retain rights in other global markets, and Sentynl will also receive global manufacturing rights. Alvelestat is an oral neutrophil elastase inhibitor that is being prepared for Phase 3 development and, if approved, could potentially become the first oral treatment for AATD-LD, a rare genetic lung disorder estimated to affect around 50,000 to 80,000 people in the US. The Phase 3 programme is expected to begin in early 2027, with Mereo leading the global study and regulatory discussions until completion. Mereo will receive a non-refundable option fee, while exercising the option could make it eligible for up to $40 million in upfront and R&D payments through the filing of a New Drug Application, along with double-digit tiered royalties on US net sales. Alvelestat has already received Orphan Drug Designation from both the US FDA and European Commission, as well as Fast Track designation from the FDA. From an analytical perspective, the agreement gives Zydus an opportunity to add a potentially differentiated rare-disease therapy to its US portfolio, although the commercial opportunity remains dependent on successful Phase 3 development, regulatory approval and eventual market adoption. $ZYDUSLIFE Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.